Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9

Maryam Amiri, Amir Kian Moaveni, Masoumeh Majidi Zolbin, Behrouz Shademan, Alireza Nourazarian

Open source

DOI
10.3389/fimmu.2024.1462697
Published
2024-11-08
Container
Frontiers in Immunology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2024.1462697,
  title = {Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9},
  author = {Maryam Amiri and Amir Kian Moaveni and Masoumeh Majidi Zolbin and Behrouz Shademan and Alireza Nourazarian},
  year = {2024},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2024.1462697},
  url = {https://doi.org/10.3389/fimmu.2024.1462697}
}

RIS

TY  - JOUR
TI  - Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9
AU  - Maryam Amiri
AU  - Amir Kian Moaveni
AU  - Masoumeh Majidi Zolbin
AU  - Behrouz Shademan
AU  - Alireza Nourazarian
PY  - 2024
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2024.1462697
UR  - https://doi.org/10.3389/fimmu.2024.1462697
ER  - 

APA

Amiri, M., Moaveni, A. K., Zolbin, M. M., Shademan, B., & Nourazarian, A. (2024). Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1462697

Source records